Brand-name vs compounded GLP-1s

The gap, in verified numbers

What the providers themselves say

• ◆Alloy: “Unlike FDA-approved drugs, compounded medications are not reviewed by the FDA for safety, effectiveness, or quality.”
• ◆Brello Health: “Compounded drug products are not FDA-approved, and the FDA does not evaluate their safety, effectiveness, or quality.”
• ◆Ivím Health: “Semaglutide is presently only available as prescription brand name products, Wegovy® and Ozempic®,” and “compounded semaglutide medication is not covered by insurance.”
• ◆Sesame: “Compounded semaglutide is not currently available through Sesame.”

It is worth noticing that the clearest statements of the compounding caveat come from the companies selling compounded products. That is to their credit, and it also means no buyer can claim they were not told.

The dosing difference nobody advertises

A brand-name pen delivers a fixed dose. A compounded vial requires drawing a measured volume into a syringe, and the concentration varies between compounders. FDA has published an alert about dosing errors with compounded semaglutide, describing reports of adverse events “some requiring hospitalization” that may relate to overdoses.

If you go the compounded route, the single most useful question is what concentration the vial is and whether your dose is expressed in units or millilitres — and to have the answer written down rather than remembered.

When each one makes sense

• ◆Brand-name, via a manufacturer programme, if you can get a prescription and want the approved product at $149–$449/month.
• ◆Brand-name, via insurance, if your plan covers it — the savings cards go as low as $25/month with commercial cover.
• ◆Compounded, if the manufacturer routes are closed to you and you have read the caveat and accepted it.
• ◆Neither, if the only affordable option is one you would not choose on its merits — that is a conversation to have with a clinician, not a checkout page.